Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
NCT07819604Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2027
01
Overview
A Phase 2 trial of serplulimab in colorectal cancer (CRC), sponsored by Xijing Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07819604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819604.